Wedbush Remains Neutral on BioMarin Pharma (BMRN) - PT to $104
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
BioMarin Pharma (BMRN): Cutting PT on PDFUA Extension and Financing - Wedbush
September 7, 2016 7:33 AM EDTWedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after PDUFA date for Brineura for CLN2 disease was delayed to April 27, 2017 and an advisory committee meeting was announced.
The analyst considers the PDUFA extension and plans... More
BioMarin Pharma (BMRN) Offers Cerliponase Alfa Program Update; Says ML Scores Consistent with BLA
September 6, 2016 4:08 PM EDTBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced a program update for cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1) to treat children with CLN2 disease, a form of Batten disease. CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments, where the majority of affected children lose their ability to walk and talk by approximately six years of age. After 81 weeks, patients treated with cerliponase alfa continue to have motor-language (ML) scores representing substantial attenuation of disease progression compared to natural history. These data... More
